Jean-Pierre Gotteland

rct

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials

Lancet (London, England) ·doi:10.1016/S0140-6736(22)01475-1

BACKGROUND: Uterine fibroids are common non-cancerous neoplasm that cause heavy menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone receptor antagonist taken once per day that dose-dependently suppresses…

article 2021

A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis

British journal of clinical pharmacology ·doi:10.1111/bcp.15171

AIMS: To identify linzagolix doses, an oral GnRH receptor antagonist, that effectively lower oestradiol (E2) to relieve endometriosis-related pelvic pain without compromising bone health. METHODS: Integrated statistical, pharmacokinetic-pha…

article 2020

Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding—delayed add-back onset does not improve bleeding pattern

Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1007/s43032-020-00172-z

article 2020

Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial

Fertility and sterility ·doi:10.1016/j.fertnstert.2020.02.114

article 2015

Bentamapimod (JNK Inhibitor AS602801) Induces Regression of Endometriotic Lesions in Animal Models

Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719115600553

article 2015

c-Jun NH2-terminal kinase inhibitor bentamapimod reduces induced endometriosis in baboons: an assessor-blind placebo-controlled randomized study

Fertility and sterility ·doi:10.1016/j.fertnstert.2015.11.022